Fig. 7 | Scientific Reports

Fig. 7

From: Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B

Fig. 7

Comparison of mean bone mineral density at 240 weeks. (a) Comparison of the lumbar spine: following lumbar spine examination, the baseline values were 0.903 ± 0.035 g/cm2 vs. 0.814 ± 0.042 g/cm2 at 240 weeks in the ETV continuation group and 0.939 ± 0.035 g/cm2 vs. 0.859 ± 0.041 g/cm2 at 240 weeks in the TAF continuation group, with no significant differences (p = 0.176 and 0.216, respectively). (b) Comparison of femur: following the femoral examination, the baseline values in the ETV continuation group were 0.656 ± 0.028 g/cm2 vs. 0.561 ± 0.032 g/cm2 at 240 weeks and 0.690 ± 0.023 g/cm2 vs. 0.600 ± 0.033 g/cm2 at 240 weeks in the TAF continuation group, both showing decreased symptoms (p = 0.081 and 0.047, respectively). ETV entecavir, TAF tenofovir alafenamide.

Back to article page